Inhibikase Therapeutics (IKT) EPS (Weighted Average and Diluted) (2021 - 2026)
Inhibikase Therapeutics (IKT) has 6 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.1 in Q1 2026.
- On a quarterly basis, EPS (Weighted Average and Diluted) rose 33.33% to -$0.1 in Q1 2026 year-over-year; TTM through Mar 2026 was -$0.43, a 27.12% increase, with the full-year FY2025 number at -$0.49, up 57.76% from a year prior.
- EPS (Weighted Average and Diluted) reached -$0.1 in Q1 2026 per IKT's latest filing, down from -$0.09 in the prior quarter.
- Over the last five years, EPS (Weighted Average and Diluted) for IKT hit a ceiling of $0.87 in Q4 2024 and a floor of -$1.1 in Q2 2022.
- A 5-year average of -$0.49 and a median of -$0.66 in 2024 define the central range for EPS (Weighted Average and Diluted).
- Peak YoY movement for EPS (Weighted Average and Diluted): tumbled 488.89% in 2022, then surged 227.94% in 2024.
- Tracing IKT's EPS (Weighted Average and Diluted) over 5 years: stood at -$1.02 in 2022, then soared by 33.33% to -$0.68 in 2023, then surged by 227.94% to $0.87 in 2024, then tumbled by 110.34% to -$0.09 in 2025, then fell by 11.11% to -$0.1 in 2026.
- Business Quant data shows EPS (Weighted Average and Diluted) for IKT at -$0.1 in Q1 2026, -$0.09 in Q4 2025, and -$0.13 in Q3 2025.